Does dapagliflozin improve functional outcomes and safety in symptomatic patients with systemic right ventricular dysfunction on sacubitril/valsartan?
Dapagliflozin appears safe and provides functional benefits for patients with systemic right ventricular dysfunction already receiving sacubitril/valsartan, warranting larger randomized trials.
This is the first study, to our knowledge, demonstrating the functional benefits and safety of dapagliflozin in symptomatic patients with sRV dysfunction under medical treatment with sacubitril/valsartan. These results support the need for larger randomized trials to further evaluate this therapeutic option in this population.
Albertini et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: